VFEND
What it isTriazole inhibiting fungal CYP51; invasive aspergillosis.
Why this oneIt is first-line for invasive aspergillosis and penetrates the CNS and eye.
What limits itNon-linear kinetics with CYP2C19 variation demanding level monitoring. Visual disturbance, photosensitivity with skin cancer, and periostitis.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Invasive aspergillosis | adult | 6 mg/kg IV q12h x24h (load) | 4 mg/kg IV q12h or 200 mg PO BID | 4 mg/kg IV q12h |
| Candidemia / deep-tissue Candida | adult | 3-4 mg/kg IV q12h | 3-4 mg/kg IV q12h or 200 mg PO BID | 4 mg/kg IV q12h |
| Scedosporiosis and Fusariosis | adult | 4 mg/kg IV q12h | 4 mg/kg IV q12h or 200 mg PO BID | 4 mg/kg IV q12h |
| Esophageal candidiasis | adult | 200 mg PO BID | 200 mg PO BID | 200 mg PO BID |
| Invasive fungal infections | pediatric 2-<12y | 9 mg/kg IV q12h x24h (load) | 8 mg/kg IV q12h or 9 mg/kg PO BID (max 350 mg) | 9 mg/kg PO BID (max 350 mg) |
Renal Avoid IV formulation if CrCl <50 mL/min (moderate-severe) due to vehicle accumulation
Hepatic Use half the maintenance dose in mild-moderate impairment (Child-Pugh A/B)
Pregnancy Can cause fetal harm (animal malformations)
Lactation Undefined
NO BOXED WARNINGS
Principal riskNon-linear kinetics needing level monitoring; visual disturbance
Cost, est. cash$20–$1,500/dose or month
Generic entry2010
Legacy pregnancy categoryD
Defining liabilityHepatotoxicity, visual/neuropsychiatric effects, QT risk and extensive CYP interactions.

Open Voriconazole in the interactive console ↗
